Download Files:
Products Details
Product Description
– BDA-366 is a potent Bcl2 antagonist (Ki = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells[1].
Web ID
– HY-101083
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C24H29N3O4
References
– [1]Han B, Park D, Li R, et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015;27(6):852-863.
CAS Number
– 1909226-00-1
Molecular Weight
– 423.50
SMILES
– O=C1C2=C(C(NC[C@H]3CO3)=CC=C2NC[C@H](O)CN(CC)CC)C(C4=CC=CC=C41)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Bcl-2 Family
Isoform
– Bcl-2
Pathway
– Apoptosis
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
